



# **Trinidad and Tobago**


## **Requirements for Bioequivalence Studies**

Sham Bissessar  
Ministry of Health



## Generic Drug Products Requirements to the Innovator Product

- Must conform to the same **standards**
  - quality
  - safety
  - efficacy.
- Same **basic and technical data** required for assessment.
- Must shown to be **pharmaceutically equivalent**
  - Data about the therapeutic equivalence may be required.




# Generic Drug Products

- Requirements to assess equivalence:
  - Comparative bioequivalence
  - Comparative pharmacodynamic studies in humans
    - when the quantitative analysis of the API(s) and/or the metabolites in plasma, blood or urine cannot be made with a high degree of accuracy
  - Comparative clinical trials
  - In vitro dissolution tests.



# Regulatory Basis

- Food and Drugs Act Chapter 30:01 (Act No. 8 of 1960)
  - Amended by: 39 of 1968 /156 of 1972 /\*31 of 1980 /16 of 1986 /12 of 1987 /6 of 1993 /16 of 1998/ 6 of 2005
  - <http://rgd.legalaffairs.gov.tt/Laws/Chs.%2028-31/30.01/30.01%20aos.htm>
- Annex 3: Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability
  - (WHO, 1999)
  - [www.who.int/medicines/services/expertcommittees/pharmprep/QAS04\\_093Rev4\\_final.pdf](http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf)



# Other Guidelines

- Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations
  - (FDA, 2003)
  - <http://www.fda.gov/cder/guidance/5356fnl.htm>
- Note for Guidance on Investigation of Bioavailability and Bioequivalence
  - (EMA, 2001)
  - <http://www.emea.europa.eu/pdfs/human/ewp/140198en.pdf>



# Other Guidelines

- Conduct and Analysis of Bioavailability and Bioequivalence Studies
  - Part A: Oral Dosage Formulations used for Systemic Effects, 1992;
  - Part B: Oral Modified Release Formulations, 1996
    - (Health Canada, 1996)
    - [http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/bio-b\\_e.html](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/bio-b_e.html)



# Concerns

1. Analytical Method
2. Plasma Level-Tissue Curves and AUC
3. Independence
4. Compliance



# **1 *Analytical Method***

- HPLC with UV detector
- LC-MS
- Method validation details to be provided
  - sensitivity
  - selectivity
  - precision
  - inter- and intra-day variability
  - minimum detectable amount
  - percent recovery (when an extraction is involved)



# **1 *Analytical Method***

- Submit representative chromatograms
  - to determine quality of chromatography
    - peak width
    - retention time
    - resolution of analyte
      - from an internal standard
      - other materials in the sample



# **1 *Analytical Method***

- For derivatization procedures
  - internal standard that is also derivatized
- Provide calibration curves
- For chiral HPLC columns
  - chromatogram must show the resolution of isomers.



## 2 Plasma Concentration-Time Curves and AUC

- Minimum of eighteen (18) volunteers
- Plasma sample collection
  - a period long enough to characterize the elimination phase
  - Generally three half-lives
- Plasma profile of both test and reference sample submitted for each volunteer.



## 2 Plasma Concentration-Time Curves and AUC

- Statistical analysis required:
  - ANOVA test on log transformed AUC
  - Both  $AUC_{0-t}$  and  $AUC_{0-\infty}$
  - Table of  $C_{max}$ ,  $t_{max}$ , AUC for test/standard



# 3 Independence

- Study center should be independent
- Chief analyst/investigator's qualification and experience
  - Bioequivalence study
    - Study design and protocol
  - Data interpretation




# 4 Compliance

- Annex 3: Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability

– (WHO, 2005)

[http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04\\_093\\_Rev4\\_final.pdf](http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093_Rev4_final.pdf)



# 4 Compliance

- WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI-  
Ethical Principles for Medical Research Involving Human  
Subjects Adopted by the 18th WMA General Assembly,  
Helsinki, Finland, June 1964,
  - amended by the
    - 29th WMA General Assembly, Tokyo, Japan, October 1975
    - 35th WMA General Assembly, Venice, Italy, October 1983
    - 41st WMA General Assembly, Hong Kong, September 1989
    - 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996
    - and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000
    - Note of Clarification on Paragraph 29 added by the WMA General Assembly, Washington 2002
    - Note of Clarification on Paragraph 30 added by the WMA General Assembly, Tokyo 2004
      - (WMA, 2004)
      - <http://www.wma.net/e/policy/pdf/17c.pdf>